Marshall Wace North America’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Marshall Wace North America’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,815	Closed	-$603K	–	1981
2021 Q1	$603K	Buy	+8,815	New	+$713K	﹤0.01%	1153
2019 Q3	–	Sell	-110,998	Closed	-$4.86M	–	1694
2019 Q2	$4.86M	Buy	+110,998	New	+$6.26M	0.03%	373

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Marshall Wace North America's BHVN Position: Q2 2021 in Review

Marshall Wace North America sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2021, closing a stake of 8,815 shares — an estimated $603K sold.

Marshall Wace North America first reported a position in BHVN in Q2 2019 and held it in 2 quarters. The position peaked at $4.86M in Q2 2019. 223 funds tracked by Wall St. Rank hold BHVN as of Q2 2021.

Marshall Wace North America reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 8,815 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2021, an estimated $603K.
Marshall Wace North America first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 2 quarters.
Marshall Wace North America's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $4.86M in Q2 2019.
223 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.